Kringle Pharma Narrows Loss Forecast After Signing Maruishi Licensing Deal
Kringle Pharma raised its annual sales guidance and narrowed its projected loss for the year to September 2026 after signing an exclusive Japan licensing deal with Maruishi Pharmaceutical for an experimental vocal-fold-scar treatment, under which it will record a ¥100 million upfront fee as revenue this fiscal year, with roughly half of the improved loss forecast coming instead from ¥108 million of development spending that shifted into next year.